Yale-led technology receives first-ever FDA approval for breast cancer treatment

May 8, 2026 - 00:11

A new breast cancer treatment rooted in Yale University research has received its first-ever approval from the U.S. Food and Drug Administration. The therapy, developed by the biotech company Arvinas, targets a specific type of advanced breast cancer and marks a major milestone for a technology known as PROTAC.

Arvinas was originally founded based on pioneering research from Yale chemist Craig Crews into PROTAC protein degraders. Unlike traditional drugs that block a protein's function, PROTACs work by tagging harmful proteins inside cells for destruction. The approach has been studied for years, but this is the first time the FDA has cleared a PROTAC-based drug for patient use.

The newly approved treatment is designed for adults with a certain form of metastatic breast cancer that has stopped responding to other therapies. Clinical trials showed the drug could shrink tumors or slow disease progression in patients who had few remaining options. The approval is seen as a validation of the PROTAC platform, which researchers hope can be applied to other cancers and diseases in the future.

Yale officials called the decision a testament to decades of basic science. Crews, who holds a joint appointment in chemistry and pharmacology, said the approval represents a shift in how medicine can attack disease at the molecular level. The drug will be marketed under the brand name Vepdegestrant.